AbstractBySubCategory

Multidisciplinary Treatment

Cancers of the Esophagus and Stomach

2013 Gastrointestinal Cancers Symposium

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.sort descending
Patient-reported outcomes from a phase III multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing after chemotherapy: Cancer Oesophagus Gefitinib (COG). Susan J. Dutton 06
Final results of RTOG 0246: A phase II study of selective surgical resection for locoregionally advanced esophageal cancer treated with a paclitaxel-based chemoradiation regimen. Stephen Swisher 07
Long-term oncologic outcomes of robotic gastrectomy for gastric cancer compared with laparoscopic gastrectomy. Woo Jin Hyung 08
Predicting survival in stomach cancer: The role of quality-of-life assessment. Donald Peter Braun 100
Prognostic impact of postoperative radiation in patients with radical esophagectomy and pathologic lymph nodes positive esophageal cancer. Yaping Xu 101
Fast track multidisciplinary approach for gastrointestinal tumours. Kristien M. A. J. Tytgat 102
Optimal criteria of treatment change for advanced gastric cancer patients with nonmeasurable peritoneal metastasis alone. Hiroko Hasegawa 103
The impact of modified Glasgow prognostic score on survival in patients with gastric cancer. Hironobu Goto 104
Activity of AT13387, a novel, non-ansamycin inhibitor of heat shock protein 90, against gastrointestinal stromal tumors (GIST). Daruka Mahadevan 105
Significance of accurate HER2 testing as a new biomarker in advanced gastric cancer. Tetsuya Kusumoto 106
New endoscopic treatment for superficial carcinoma of borderline lesions between the cervical esophagus and hypopharynx. Hirofumi Kawakubo 107
Incidence of brain metastases following trimodality therapy (TMT) in patients with esophageal and gastroesophageal (E-EGCJ) cancer. Roopma Wadhwa 108
Association of increased survival with surgery and radiation therapy in metastatic gastric cancer: A SEER database analysis. Ravi Shridhar 109
C-reactive protein as an independent prognostic factor for metastatic gastric cancer. Mika Kitagawa 110
16-covariate propensity score matching between trimodality (TMT)-eligible esophagogastric cancer (EC) patients who had surgery and those who declined surgery after preoperative chemoradiation. Takashi Taketa 111
A retrospective comparison study of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received fluoropyrimidine and platinum-based chemotherapy. Tsuyoshi Shirakawa 112
PCF chemotherapy combined with surgical treatment of advanced gastric cancer. Cheng Xiangdong 113
Prognostic significance of HER2 expression and associated clinical characteristics in esophageal adenocarcinoma. Ellie Chan 114
Combination external beam radiotherapy and brachytherapy for radical treatment of esophageal carcinoma in patients not suitable for surgery or chemoradiation. Ajay Aggarwal 115
Single-center experience with paclitaxel (T), carboplatin (C), and capecitabine (X) in the treatment of advanced esophagogastric cancer. Carl Alex Ruoff 116
Robotic-assisted Ivor Lewis esophagectomy with or without neoadjuvant chemoradiation therapy for esophageal cancer. Franz Omar Smith 117
Relationship of drain amylase and anastomotic leak after esophagectomy. Joshua S. Hill 118
Concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil (5 FU) and cisplatin for locally advanced resectable esophageal cancer: A retrospective study. Khaldoun Almhanna 119
Various clinical outcomes in patients with esophageal or gastroesophageal junction (E-GEJ) adenocarcinoma undergoing trimodality therapy: Prognostic implications. Akihiro Suzuki 120
An open, multicenter, phase II clinical trial to evaluate efficacy and safety of S-1 split cisplatin in patients with advanced gastric cancer (AGC): HGCSG0702—Safety analysis. Ichiro Iwanaga 121
Resting palliative chemotherapy in patients with gastric cancer. Hee Yeon Lee 122
Impact of pathologic complete response to preoperative docetaxel-based chemotherapy on disease-free survival in esophagogastric adenocarcinoma. Sylvie Lorenzen 123
Neoadjuvant DCF in resectable esophageal cancer: Single-center experience. Vanita Noronha 124
Survival and toxicity with intensity modulated radiation therapy (IMRT) and chemotherapy for esophageal carcinoma, with or without surgery. Kristin Kowalchik 125
Incidence of brain metastases in HER2+ gastric or esogastric junction adenocarcinoma. Christophe Blay 126
Efficacy and safety of endoscopic submucosal dissection for superficial squamous esophageal neoplasia: A systematic review and meta-analysis of the literature. Joon Sung Kim 127
Chemotherapy (CT) treatment patterns and neutropenia management in gastric cancer patients (pts) receiving myelosuppressive chemotherapy in Europe. Ewa Kalinka-Warzocha 128
Retrospective study regarding the efficacy of second- or higher-line chemotherapy (CT) of patients in advanced or recurrent gastric cancer (ARGC) after the failure of S-1 or S-1 combination chemotherapy (S+α). Kazuma Kobayashi 129
A prospective comparison of the FACT-e and EORTC-QLQC30 and OG25 questionnaires for evaluating changes in health-related quality of life in patients with esophageal cancer. Gail Darling 130
Preventive effect of rikkunshito, traditional Japanese medicine, for chemotherapy-induced nausea and vomiting. Shinya Kajiura 131
Significance of multimodality therapy for esophageal cancer synchronously or metachronously associated with head and neck cancer. Yasue Kimura 132
Combination therapy with radiation and weekly paclitaxel/carboplatin as definitive treatment for locally advanced esophageal cancer. Mark Doherty 133
Brain metastasis from esophageal cancer: Changing pattern of failure? Jonathan Ben Ashman 134
Is neoadjuvant therapy beneficial in clinically staged T2N0 esophageal cancer? Taranjeet Kaur 135
Effectiveness of percutaneous radiofrequency ablation for metachronous liver metastases of gastric cancer. Jun-Eul Hwang 136
Clinical characteristics of recurrent esophageal cancer after definitive chemoradiotherapy for stage II//III (non T4) esophageal squamous cell cancer. Akiko Nishikawa 137
A retrospective study of neoadjuvant DCF (docetaxel, cisplatin, 5-fluorouracil) for locally advanced gastric or gastro-esophageal junction adenocarcinoma (GC). Raquel Castellanos 138
A comparison of outcomes for 3D conformal versus intensity modulated radiation therapy in postoperative gastric cancer. Emory McTyre 139
Prognostic factors after R2 surgery in patients with advanced gastric cancer. Masanori Tokunaga 140
Randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin for first-line treatment of advanced gastric cancer. Katsuhiko Higuchi 60
Randomized phase III trial of irinotecan plus cisplatin versus irinotecan alone after S-1 based chemotherapy failure for patients with advanced and recurrent gastric cancer (AGC) (TCOG GI-0801). Ken Shimada 61
The role of surgical resection following imatinib treatment in patients with metastatic or recurrent GIST. Seong Joon Park 62
Efficacy and safety of trastuzumab (T-mab) and paclitaxel for T-mab naïve patients with HER2 positive previously treated metastatic gastric cancer (JFMC45-1102). Akira Miki 63
Randomized phase II study comparing dose-escalated weekly paclitaxel (wPTX) versus standard-dose wPTX for patients with previously treated advanced gastric cancer (AGC). Daisuke Takahari 64
Final results of a phase II multicenter study of neoadjuvant S-1 and irinotecan in patients with locally advanced gastric cancer. Masanori Terashima 65
Prediction of gastric cancer survival after gastrectomy using nomogram from 10,621 patients: Developed and validated using international databases. Yanghee Woo 66
A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led study. Deirdre Jill Cohen 67
A NSQIP comparison of modern multicenter results for transhiatial versus transthoracic esophagectomy. Wesley A. Papenfuss 68
Efficacy analyses of a randomized phase III clinical trial of combined therapy with CPT-11/CDDP versus CPT-11 alone in patients with advanced or recurrent gastric cancer refractory to prior S-1 chemotherapy. Hitoshi Inagaki 69
A phase ll study of trastuzumab in combination with triweekly S-1 plus CDDP in HER2-positive advanced gastric cancer (HERBIS-1). Naotoshi Sugimoto 70
Induction of pathologic complete response by long-term neoadjuvant chemotherapy for gastric cancer: Early results of a randomized phase II study—A COMPASS trial. Kazuaki Tanabe 71
Randomized phase II study of S-1/CDDP plus TSU-68 versus S-1/CDDP in patients with advanced gastric cancer. Kensei Yamaguchi 72^
A phase I dose-finding study of vorinostat (V) combined with capecitabine (X) and cisplatin (P) as first-line therapy in patients with advanced gastric cancer. Changhoon Yoo 73
Phase II study of docetaxel (DTX) and S-1 as neoadjuvant chemotherapy for potentially R0 advanced gastric cancer. Yasunori Emi 74
Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: Analysis of the Surveillance, Epidemiology and End Results (SEER)-Medicare database. Adam J. Olszewski 75
Comparative outcomes for 3D conformal versus intensity modulated radiation therapy for esophageal cancer. Jessica Freilich 76
Association of increased time from chemoradiation (CRT) to esophagectomy (E) with increased surgical complications (Cx) in esophageal cancer (EC). Joshua E. Meyer 77
Reporting of subgroup analyses (SGA) in phase III randomized trials in gastrointestinal (GI) cancer. Sarah Rachel Barton 78
Association of trimodality therapy (TMT) with rate of local-regional relapse and rare luminal-only relapse for patients with esophageal and esophagogastric junction (E-EGJ) cancer: Implications for the surveillance strategy. Kazuki Sudo 79
Association of low serum levels of transforming growth factor β1 (TGF-β1) and high levels of vascular endothelial growth factor-A (VEGF-A) following neoadjuvant chemoradiotherapy with poor outcome in esophageal cancer patients receiving combined modality therapy: A preliminary analysis using proximity ligation assay. Madeline S Graber 80
The impact of positive margins on outcome among patients with gastric cancer treated with radiation. Jonathan D. Schoenfeld 81
Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients. John Theodorus Plukker 82
The impact of race on gastric cancer outcomes in the United States. Benjamin Daniel Powers 83
Phase I study of neoadjuvant chemoradiotherapy as an outpatient setting for patients with resectable advanced gastric cancer. Tsunehiro Takahashi 84
Long-term survival of EMR-PDT for gastric cancer. Hiroyuki Narahara 85
A phase I dose-finding study of everolimus in combination with capecitabine and oxaliplatin (XELOX) as the first-line chemotherapy for patients with advanced gastric cancer. Inkeun Park 86
Phase II trial of miniDOX (reduced-dose docetaxel/oxaliplatin/capecitabine) in “suboptimal” patients with advanced gastric cancer (AGC): TTD 08-02. Fernando Rivera 87
Impact of pretreatment systemic inflammatory response on survival in AGC patients receiving first-line chemotherapy. Kazumasa Fujitani 88
Preoperative chemoradiotherapy (CRT) in gastric cancer. Anouk Kirsten Trip 89
Does radiation therapy increase late cardiac death in patients with esophageal cancer? Chi Lin 90
Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response and prolonged stable disease observed in adenocarcinoma. Geoffrey Y. Ku 91
IMAGE, a randomized phase Ib/II study of elisidepsin (E) as a single agent in pretreated advanced gastroesophageal (GE) cancer. Ramon Salazar 92
Post-progression survival (PPS) and improvements in progression-free survival (PFS) in randomized controlled trials (RCTs) in advanced gastric cancer (AGC). Kohei Shitara 93
Phase II study of preoperative chemotherapy plus bevacizumab with early salvage therapy based on FDG-PET response in patients with locally advanced gastric and GEJ adenocarcinoma. Elizabeth Won 94
Association of relapse in patients with esophageal and esophagogastric junction (E-EGJ) cancer with surgical stage after trimodality therapy (TMT): Implications for customized surveillance. Maria-Claudia Campagna 95
Gastrectomy after intravenous and intraperitoneal paclitaxel combined with oral S-1 for gastric cancer with peritoneal metastasis. Joji Kitayama 96
Early decline of CA125 to chemotherapy in advanced gastric cancer with peritoneal effusion. Takayuki Ando 97
Survival in patients with esophageal cancer treated with surgery after chemoradiotherapy. Ravi Shridhar 98
Patterns of locoregional relapses for patients with esophageal cancer for whom exclusive chemoradiotherapy failed: A plea for dose escalation and elective nodal irradiation. Cedric Chevalier 99
SCOPE 1: A phase II/III trial of chemoradiotherapy in esophageal cancer plus or minus cetuximab. Thomas Crosby LBA3
Cougar-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma. Hugo Ford LBA4
REGARD: A phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy. Charles S. Fuchs LBA5